A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Author： Chiorean E.   Dragovich Tomislav   Hamm John   Langmuir Virginia   Kroll Stewart   Jung Donald   Colowick Alan   Tidmarsh George   Loehrer Patrick  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.61, Iss.6, 2008-05, pp. : 1019-1026

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

By Schelman William   Morgan-Meadows Sherry   Bailey Howard   Holen Kyle   Thomas James   Eickhoff Jens   Brandon Heidi   Oliver Kate   Alberti Dona   Wilding George  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 727-733

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

By Flaherty Keith   Stevenson James   Redlinger Maryann   Algazy Kenneth   Giantonio Bruce   O’Dwyer Peter  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 5, 2004-05 ,pp. : 404-408

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors

By Schneider Bryan   Fukunaga Anna   Murry Daryl   Yoder Christy   Fife Karen   Foster Anne   Rosenberg Leslie   Kelich Stephanie   Li Lang   Sweeney Christopher  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 261-268

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite